君实生物：PD-1收到FDA完整回复函，要求进行一项质控流程变更
5月2日，君实生物发布公告，PD-1抗体特瑞普利单抗的上市申请收到FDA的完整回复函(CRL)，要求进行一项质控流程变更。君实生物认为该变更较容易完整。君实生物计划在2022年仲夏之前重新递交上市申请。完整回复函中还提到，现场核查因为新冠疫情受阻，具体核查时间另行通知。
文章内容来源于网络，如有侵权，请联系客服删除处理！
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
HSBC shares outperform after top shareholder calls for bank's break-up By Reuters
涉嫌非法汇款？被印度扣押约48亿元资产！小米回应：合法商业行为
Related News
